SAN FRANCISCO, October 31, 2018 /PRNewswire/ --
The global atopic dermatitis drugs market size is expectedto reach USD 6.41 billion by 2022, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.6% during the forecast period. Various factors such as emergence of novel therapeutics and growing uptake
(Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )
Eucrisa (Pfizer; crisaborole ointment) was approved by the U.S. FDA for treatment of atopic dermatitis (AD), in 2016. The drug is indicated for mild-to-moderate AD in patients who are two years or older, meeting a key therapeutics need of the market. Dupixent (Sanofi/Regeneron) was the first biologic to be launched in 2017 for management of AD. The drug is under clinical investigation for use in pediatric population.
Several promising candidates, especially biologics and small molecules, in pipeline are expected to alter the AD therapeutic landscape post launch. Nemolizumab is anticipated to be the first biologic (anti-IL-13) indicated for itching associated with atopic dermatitis. Tralokinumab, an IL-13 inhibitor, is under evaluation for safety and efficacy of treatment of moderate-to-severe AD.
Upcoming patent expiration of key products, such as LEO Pharma's Protopic, Mylan/Valeant's Elidel, and Bayer's Desonate will result in generic penetration in therapeutic space. However, novel therapeutics, such as Eucrisa and Dupixent, are likely to gain traction over the forecast period and attain blockbuster status.
Underdeveloped and unserved categories such as rarer subtypes and pediatric population offer strong commercial opportunities. Drug companies are currently investigating multiple treatment options in niche indications such as severe refractory atopic dermatitis. Improving availability of new treatment modalities and targeted approaches offer a promising future for the global atopic dermatitis drugs market.
Browse full research report with TOC on "Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics), By RoA, And Segment Forecasts, 2016 - 2022" at: https://www.grandviewresearch.com/industry-analysis/atopic-dermatitis-drugs-market
Further Key Findings From the Report Suggest:
Browse related reports by Grand View Research:
Grand View Research has segmented the global atopic dermatitis drugs market based on drug class, route of administration, and region:
Explore the BI enabled intuitive market research database, Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email: firstname.lastname@example.org
SOURCE Grand View Research, Inc.
Subscribe to our Free Newsletters!